Aligos Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview

Aligos Therapeutics

08/03/2024 21:06

* Aligos Therapeutics Inc  ALGS.OQ   ALGS.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 12
for the period ending December 31 2023
    * The South San Francisco California-based  company is
expected to
report a 54.8% decrease in revenue to $1.6 million from $3.54
million a year ago, according to the mean estimate from 2
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Aligos Therapeutics Inc
is for
a loss of 27 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aligos
Therapeutics Inc is $4.00​, above​ its last closing price
of $0.93. ​​​

This summary was machine generated March 8 at 21:06 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)